Exploring the benefits of in-diet versus repeated oral dosing of saracatinib (AZD0530) in chronic studies: insights into pharmacokinetics and animal welfare

Saracatinib/AZD0530 (SAR), a Src tyrosine kinase inhibitor, mitigates seizure-induced brain pathology in epilepsy models upon repeated oral dosing. However, repeated dosing is stressful and can be challenging in some seizing animals. To overcome this issue, we have incorporated SAR-in-Diet and compa...

Descripción completa

Detalles Bibliográficos
Autores principales: Vasanthi, Suraj S., Massey, Nyzil, Nair, Suresh N., Mochel, Jonathan P., Showman, Lucas, Thippeswamy, Thimmasettappa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Veterinary Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10666625/
https://www.ncbi.nlm.nih.gov/pubmed/38026620
http://dx.doi.org/10.3389/fvets.2023.1297221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10666625/
https://www.ncbi.nlm.nih.gov/pubmed/38026620
http://dx.doi.org/10.3389/fvets.2023.1297221

Ejemplares similares